Defining the cell surface proteomic landscape of multiple myeloma reveals immunotherapeutic strategies and biomarkers of drug resistance

The myeloma cell surface proteome (“surfaceome”) not only determines tumor interaction with the microenvironment but serves as an emerging arena for therapeutic development. Here, we use glycoprotein capture proteomics to first define surface markers most-enriched on myeloma when compared to B-cell malignancy models, revealing unexpected biological signatures unique to malignant plasma cells. We next integrate our proteomic dataset with existing transcriptome databases, nominating CCR10 and TXNDC11 as possible monotherapeutic targets and CD48 as a promising co-target for increasing avidity of BCMA-directed cellular therapies. We further identify potential biomarkers of resistance to both proteasome inhibitors and lenalidomide including changes in CD53, EVI2B, CD10, and CD33. Comparison of short-term treatment with chronic resistance delineates large differences in surface proteome profile under each type of drug exposure. Finally, we develop a miniaturized version of the surface proteomics protocol and present the first surface proteomic profile of a primary myeloma patient plasma cell sample. Our dataset provides a unique resource to advance the biological, therapeutic, and diagnostic understanding of myeloma.

[1]  Omer Dushek,et al.  Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function , 2020, Nature Communications.

[2]  Rebekah L. Gundry,et al.  Discovery and validation of surface N-glycoproteins in MM cell lines and patient samples uncovers immunotherapy targets , 2020, Journal for ImmunoTherapy of Cancer.

[3]  H. Einsele,et al.  CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions , 2020, Frontiers in Oncology.

[4]  Lisa E. Wagar,et al.  An Integrated Multi-omic Single-Cell Atlas of Human B Cell Identity , 2020, Immunity.

[5]  Kole T. Roybal,et al.  CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma. , 2020, Blood advances.

[6]  Donghui Wang,et al.  Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma , 2020, bioRxiv.

[7]  J. Myklebust,et al.  Tuning the Antigen Density Requirement for CAR T Cell Activity. , 2020, Cancer discovery.

[8]  Y. Ishihama,et al.  EDEM2 stably disulfide-bonded to TXNDC11 catalyzes the first mannose trimming step in mammalian glycoprotein ERAD , 2020, eLife.

[9]  Howard Y. Chang,et al.  c-Jun overexpression in CAR T cells induces exhaustion resistance , 2019, Nature.

[10]  Donghui Wang,et al.  In Vitro-Selected Nanobody-Based Cellular Therapy Targeting CD72 for Treatment of Refractory B-Cell Malignancies , 2019, Blood.

[11]  H. Geng,et al.  DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma , 2019, Leukemia.

[12]  M. Sirota,et al.  Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis , 2019, bioRxiv.

[13]  B. Law,et al.  A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis , 2019, Haematologica.

[14]  M. Schrappe,et al.  Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia. , 2019, Blood.

[15]  D. Dimitrov,et al.  Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence , 2019, Clinical Cancer Research.

[16]  Joshua M. Korn,et al.  Next-generation characterization of the Cancer Cell Line Encyclopedia , 2019, Nature.

[17]  Patrick G. A. Pedrioli,et al.  Classification of mouse B cell types using surfaceome proteotype maps , 2019, Nature Communications.

[18]  M. Sadelain,et al.  CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape , 2019, Nature.

[19]  S. Almo,et al.  GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells , 2019, Science Translational Medicine.

[20]  Angela N. Brooks,et al.  Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma , 2018, bioRxiv.

[21]  W. Shi,et al.  IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos. , 2018, Blood.

[22]  Olga T. Schubert,et al.  The in silico human surfaceome , 2018, Proceedings of the National Academy of Sciences.

[23]  A. Wiita,et al.  Seeking Convergence and Cure with New Myeloma Therapies. , 2018, Trends in cancer.

[24]  Adam Bagg,et al.  Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia , 2018, Cell.

[25]  A. Órfão,et al.  Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials , 2018, Leukemia.

[26]  Max A. Horlbeck,et al.  Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins , 2018, eLife.

[27]  G. Morgan,et al.  Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma , 2017, Leukemia.

[28]  Stephen T. C. Wong,et al.  The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma , 2017, Molecular Cancer Therapeutics.

[29]  Lei Deng,et al.  CCL28 chemokine: An anchoring point bridging innate and adaptive immunity , 2017, International Immunopharmacology.

[30]  A. Mitra,et al.  Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry , 2017, Leukemia & lymphoma.

[31]  Phillip G. Montgomery,et al.  Defining a Cancer Dependency Map , 2017, Cell.

[32]  H. Einsele,et al.  Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab. , 2017, Blood.

[33]  R. Gale,et al.  Gemtuzumab ozogamicin in acute myeloid leukemia , 2017, Leukemia.

[34]  Devin P. Sullivan,et al.  A subcellular map of the human proteome , 2017, Science.

[35]  Jüergen Cox,et al.  The MaxQuant computational platform for mass spectrometry-based shotgun proteomics , 2016, Nature Protocols.

[36]  Ruedi Aebersold,et al.  Mass-spectrometric exploration of proteome structure and function , 2016, Nature.

[37]  Marco Y. Hein,et al.  The Perseus computational platform for comprehensive analysis of (prote)omics data , 2016, Nature Methods.

[38]  G. Dougan,et al.  Genetic dissection of mammalian ERAD through comparative haploid and CRISPR forward genetic screens , 2016, Nature Communications.

[39]  B. Everts,et al.  Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism , 2016, Leukemia.

[40]  R. Aebersold,et al.  On the Dependency of Cellular Protein Levels on mRNA Abundance , 2016, Cell.

[41]  A. Órfão,et al.  Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma , 2016, Cytometry. Part B, Clinical cytometry.

[42]  N. Nikesitch,et al.  Molecular mechanisms in multiple myeloma drug resistance , 2015, Journal of Clinical Pathology.

[43]  A. Palumbo,et al.  Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. , 2015, The New England journal of medicine.

[44]  R. Groen,et al.  Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab , 2015, Leukemia.

[45]  Ruedi Aebersold,et al.  A Mass Spectrometric-Derived Cell Surface Protein Atlas , 2015, PloS one.

[46]  J. Byrd,et al.  Tetraspanins as therapeutic targets in hematological malignancy: a concise review , 2015, Front. Physiol..

[47]  J. Weissman,et al.  Validation of the Hsp70–Bag3 Protein–Protein Interaction as a Potential Therapeutic Target in Cancer , 2015, Molecular Cancer Therapeutics.

[48]  A. Órfão,et al.  Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential , 2014, Leukemia.

[49]  Hyoeun Shim,et al.  Expression of Myeloid Antigen in Neoplastic Plasma Cells Is Related to Adverse Prognosis in Patients with Multiple Myeloma , 2014, BioMed research international.

[50]  R. Kordek,et al.  CD151 in cancer progression and metastasis: a complex scenario , 2014, Laboratory Investigation.

[51]  A. Burlingame,et al.  Global cellular response to chemotherapy-induced apoptosis , 2013, eLife.

[52]  J. Keats,et al.  Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. , 2013, Cancer cell.

[53]  E. Mejstrikova,et al.  Leukemia surfaceome analysis reveals new disease-associated features. , 2013, Blood.

[54]  A. Rosenwald,et al.  The Natural Human IgM Antibody PAT-SM6 Induces Apoptosis in Primary Human Multiple Myeloma Cells by Targeting Heat Shock Protein GRP78 , 2013, PloS one.

[55]  S. Karasawa,et al.  Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide , 2012, Leukemia.

[56]  L. Yin,et al.  Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH. , 2012, Blood.

[57]  T. Nakao,et al.  CD48 as a novel molecular target for antibody therapy in multiple myeloma , 2012, British journal of haematology.

[58]  Sean C. Bendall,et al.  Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum , 2011, Science.

[59]  Ruedi Aebersold,et al.  Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins , 2009, Nature Biotechnology.

[60]  M. Mann,et al.  Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips , 2007, Nature Protocols.

[61]  C. Gahmberg,et al.  Why mammalian cell surface proteins are glycoproteins. , 1996, Trends in biochemical sciences.

[62]  R. Bataille,et al.  Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after. , 1995, Blood.